Company Profile
Jade Biosciences Stock Price, News & Catalysts
- Ticker:
- JBIO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
15.06 USD (-2.78%)
Close
Last updated: November 19, 2026
—
Market cap
Why the stock is moving
As of Nov 19, 2026, JBIO closed down 2.78% at $15.06. No new same-company headline was identified in the current news window.
Company overview
Business overview
Aerovate Therapeutics is a pulmonary-hypertension company focused on inhaled and respiratory-delivery therapies. Its business has been shaped by clinical execution in a high-catalyst disease area.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Aerovate sits in specialty biopharma.
Business Model Characteristics
The model depends on clinical data, delivery strategy, and the ability to create value in pulmonary vascular disease.
Position Within the Biotechnology Landscape
Aerovate is a high-beta pulmonary name whose stock is highly sensitive to trial and strategy updates.
Future catalysts
- Aerovate Therapeutics's catalysts are strategic repositioning and any new development path after the pulmonary-hypertension reset. The company is more of a corporate-reset story now.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Jade Biosciences (JBIO)?
Jade Biosciences (JBIO) most recently closed at 15.06 USD, a -2.78% move versus the previous session.
What does Jade Biosciences do?
Aerovate Therapeutics is a pulmonary-hypertension company focused on inhaled and respiratory-delivery therapies. Its business has been shaped by clinical execution in a high-catalyst disease area.
On which exchange is JBIO stock listed?
Jade Biosciences (JBIO) is associated with NASDAQ, United States, Biopharma.
What is Aerovate?
Aerovate Therapeutics's catalysts are strategic repositioning and any new development path after the pulmonary-hypertension reset.
Which conditions is Jade Biosciences targeting with Aerovate?
Jade Biosciences is associated with respiratory disease based on its company overview and current catalyst commentary.
How does Jade Biosciences describe recent progress with Aerovate?
Aerovate Therapeutics's catalysts are strategic repositioning and any new development path after the pulmonary-hypertension reset.
What is Therapeutics?
Aerovate Therapeutics is a pulmonary-hypertension company focused on inhaled and respiratory-delivery therapies.
What should investors watch for with Therapeutics?
Aerovate Therapeutics's catalysts are strategic repositioning and any new development path after the pulmonary-hypertension reset.
